EUVIMEDEUVIMED entdecken
Systematische Übersicht

Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review

Francesca M Cozzi, David Zuckerman, Ariel Sacknovitz, Nimrod Gozum, Arjun Syal, Fabio Danisi, Vishad Sukul

Neurosurgical Focus · 2024-06 · 56 (6) · E14

DOI: 10.3171/2024.3.focus2464 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurosurgical Focus, 2024-06. Verfasst von Francesca M Cozzi und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cam…. Hauptthemen laut MEDLINE: Baclofen, Multiple Sclerosis, Injections, Spinal, Muscle Spasticity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The purpose of this systematic review was to evaluate empirical outcomes of studies in the literature that investigated effectiveness of intrathecal baclofen (ITB) in the treatment of multiple sclerosis (MS)–related spasticity (MSRS) based on various metrics. Since the first description of this route of baclofen delivery for MS patients by Penn and Kroin in 1984, numerous studies have contributed to the medical community’s knowledge of this treatment modality. The authors sought to add to the literature a systematic review of studies over the last 2 decades that elucidates the clinical impact of ITB in treating MSRS with the following endpoints: impact on patient-centered outcomes, such as spasticity reduction (primary), complications (secondary), and dosing (secondary). METHODS The authors queried three databases (PubMed, Scopus, and Cochrane Library) using the following search terms: (intrathecal baclofen) AND (multiple sclerosis). The set inclusion criteria were as follows: 1) original, full-text article; 2) written in the English language; 3) published between and including the years 2000 and 2023; 4) discussion of pre- and post-ITB pump implantation outcomes (e.g., reduction in spasticity and improved comfort) in MSRS patients with long-term ITB treatment; and 5) contained a minimum of 5 MS patients. Data on study type, patient demographics, follow-up periods, primary outcomes, and secondary outcomes were extracted from the included studies. RESULTS The authors’ search yielded 465 studies, of which 17 met inclusion criteria. Overall, they found evidence for the effectiveness of ITB in treating MSRS patients whose condition was refractory to oral medications, with significant reported changes in spasm frequency from pre- to postimplantation. They also found evidence supporting the positive impact of ITB on MSRS patients’ quality of life. Moreover, the authors found that most complications were surgical rather than pharmacological. In addition, the average 1-year dose of ITB (reported in 7 of the included studies) was 191.93 μg/day, which is substantially lower than ITB doses reported in the literature for patients with central (non-MS) or spinal origins of spasticity at 1-year follow-up. CONCLUSIONS The evidence supports ITB as a clinically effective treatment for MSRS, particularly in patients in whom oral antispasmodics and physiotherapy have failed. This systematic review contributes a comprehensive synthesis of clinical benefits, complications, and dosing of ITB reported over the past 2 decades, which furthers an understanding of ITB’s clinical utility in practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BaclofenMultiple SclerosisInjections, SpinalMuscle SpasticityMuscle Relaxants, CentralHumansTreatment Outcome

Stichwörter der Autor:innen

intrathecal baclofenmultiple sclerosisquality of lifespasticitytreatment

Substanzen

BaclofenMuscle Relaxants, Central

Autor:innen und Institutionen

  • 1Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom.
  • 2New York Medical College, Valhalla, New York.
  • Departments of3Neurology and.
  • 4Neurosurgery, Westchester Medical Center, Valhalla, New York.

Zitieren

APA

Cozzi, F. M., Zuckerman, D., Sacknovitz, A., Gozum, N., Syal, A., Danisi, F., & Sukul, V. (2024). Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review. Neurosurgical Focus, 56(6), E14. https://doi.org/10.3171/2024.3.focus2464

Vancouver

Cozzi FM, Zuckerman D, Sacknovitz A, Gozum N, Syal A, Danisi F, et al. Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review. Neurosurgical Focus. 2024;56(6):E14. doi:10.3171/2024.3.focus2464

BibTeX
@article{Cozzi2024,
  author = {Cozzi, Francesca M and Zuckerman, David and Sacknovitz, Ariel and Gozum, Nimrod and Syal, Arjun and Danisi, Fabio and Sukul, Vishad},
  title = {Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review},
  journal = {Neurosurgical Focus},
  year = {2024},
  volume = {56},
  number = {6},
  pages = {E14},
  doi = {10.3171/2024.3.focus2464}
}
Kostenlos starten →